A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2014
At a glance
- Drugs AV 7909 (Primary) ; Anthrax vaccine
- Indications Anthrax
- Focus Adverse reactions
- Sponsors Emergent BioSolutions
- 13 Feb 2014 Results published in the Vaccine.
- 20 Aug 2012 Actual end date (June 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.